A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia
Atherosclerotic Cardiovascular Disease
Severe Hypertriglyceridemia

Interventions

DRUG: Olezarsen
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.